Shah K - Search Results

1

TRAIL on trial: preclinical advances in cancer therapy.

Stuckey DW, Shah K. Stuckey DW, et al. Among authors: shah k. Trends Mol Med. 2013 Nov;19(11):685-94. doi: 10.1016/j.molmed.2013.08.007. Epub 2013 Sep 26. Trends Mol Med. 2013. PMID: 24076237 Free PMC article. Review.

2

Real-time imaging of TRAIL-induced apoptosis of glioma tumors in vivo.

Shah K, Tang Y, Breakefield X, Weissleder R. Shah K, et al. Oncogene. 2003 Oct 9;22(44):6865-72. doi: 10.1038/sj.onc.1206748. Oncogene. 2003. PMID: 14534533

3

Inducible release of TRAIL fusion proteins from a proapoptotic form for tumor therapy.

Shah K, Tung CH, Yang K, Weissleder R, Breakefield XO. Shah K, et al. Cancer Res. 2004 May 1;64(9):3236-42. doi: 10.1158/0008-5472.can-03-3516. Cancer Res. 2004. PMID: 15126365

4

In vivo imaging of S-TRAIL-mediated tumor regression and apoptosis.

Shah K, Tung CH, Breakefield XO, Weissleder R. Shah K, et al. Mol Ther. 2005 Jun;11(6):926-31. doi: 10.1016/j.ymthe.2005.01.017. Mol Ther. 2005. PMID: 15922963 Free article.

5

Tumor therapy mediated by lentiviral expression of shBcl-2 and S-TRAIL.

Kock N, Kasmieh R, Weissleder R, Shah K. Kock N, et al. Among authors: shah k. Neoplasia. 2007 May;9(5):435-42. doi: 10.1593/neo.07223. Neoplasia. 2007. PMID: 17534449 Free PMC article.

6

MicroRNA-21 knockdown disrupts glioma growth in vivo and displays synergistic cytotoxicity with neural precursor cell delivered S-TRAIL in human gliomas.

Corsten MF, Miranda R, Kasmieh R, Krichevsky AM, Weissleder R, Shah K. Corsten MF, et al. Among authors: shah k. Cancer Res. 2007 Oct 1;67(19):8994-9000. doi: 10.1158/0008-5472.CAN-07-1045. Cancer Res. 2007. PMID: 17908999

7

Targeting multiple pathways in gliomas with stem cell and viral delivered S-TRAIL and Temozolomide.

Hingtgen S, Ren X, Terwilliger E, Classon M, Weissleder R, Shah K. Hingtgen S, et al. Among authors: shah k. Mol Cancer Ther. 2008 Nov;7(11):3575-85. doi: 10.1158/1535-7163.MCT-08-0640. Mol Cancer Ther. 2008. PMID: 19001440 Free PMC article.

8

Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy.

Sasportas LS, Kasmieh R, Wakimoto H, Hingtgen S, van de Water JA, Mohapatra G, Figueiredo JL, Martuza RL, Weissleder R, Shah K. Sasportas LS, et al. Among authors: shah k. Proc Natl Acad Sci U S A. 2009 Mar 24;106(12):4822-7. doi: 10.1073/pnas.0806647106. Epub 2009 Mar 5. Proc Natl Acad Sci U S A. 2009. PMID: 19264968 Free PMC article.

9

A dual PI3K/mTOR inhibitor, PI-103, cooperates with stem cell-delivered TRAIL in experimental glioma models.

Bagci-Onder T, Wakimoto H, Anderegg M, Cameron C, Shah K. Bagci-Onder T, et al. Among authors: shah k. Cancer Res. 2011 Jan 1;71(1):154-63. doi: 10.1158/0008-5472.CAN-10-1601. Epub 2010 Nov 17. Cancer Res. 2011. PMID: 21084267

10

Mesenchymal stem cells engineered for cancer therapy.

Shah K. Shah K. Adv Drug Deliv Rev. 2012 Jun 1;64(8):739-48. doi: 10.1016/j.addr.2011.06.010. Epub 2011 Jun 29. Adv Drug Deliv Rev. 2012. PMID: 21740940 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

4,358 results

Search Page